in black and white
Main menu
Home About us Share a book
Biology Business Chemistry Computers Culture Economics Fiction Games Guide History Management Mathematical Medicine Mental Fitnes Physics Psychology Scince Sport Technics

Methods and Principles in Medicinal Chemistry - Mannhold R.

Mannhold R., Kubinyi H., Timmerman H. Methods and Principles in Medicinal Chemistry - Wiley-VCH, 2001. - 155 p.
Download (direct link): pharmacokinetiksmedicanalchemistri2001.pdf
Previous << 1 .. 46 47 48 49 50 51 < 52 > 53 54 55 .. 56 >> Next

Elimination Half-life
The relationship between elimination half-life (t1/2) and body weight across species results in poor correlation, most probably because of the hybrid nature of this parameter [27]. A better approach may be to estimate volume of distribution and clearance by the most appropriate method and then estimate half-life indirectly from the relationship:
t1/2 = (0.693 • Vd)/Cls
1 Wandel C, Bocker RH, Bohrer H, deVries JX, Hofmann W, Walter K, Klingeist B, Neff S, Ding R, Walter-Sack I, Martin E, Drug Metab. Dispos. 1998,
26, 110-114.
2 Boxenbaum H, J. Pharmacokinet. Biopharm. 1981, 10, 201-227.
3 Boxenbaum H, D'Souza R, NATO ASI Series, Ser. A 1988, 145, Harma. Meth. Stat. App. PG.
4 Hayton WL, Health Phy. 1989, 57, 159-164.
5 Paxton JW, Clin. Exp. Pharm. Physiol. 1995, 22, 851-854.
6 Mahmood I, Balian JD, Life Sci. 1996, 59, 579-585.
7 Ritschel WA, Vachharajani NN, Johnson RD, Hussain AS, Comp. Biochem. Physiol. 1992, 103C, 249-253.
8 Mordenti J, J. Pharm. Sci. 1986, 75, 1028-1040.
9 Jezequel SG, J. Pharm. Pharmacol. 1994, 46, 196-199.
10 Beaumont KC, Causey AG, Coates PE, Smith DA, Xenobiotica 1996, 26,
11 Obach RS, Baxter JG, Liston TE, Silber M, Jones BC, MacIntyre F, Rance DJ, Wastall P, J. Pharm. Exp. Ther. 1997,
283, 48-58.
12 Lapka R, Rejholec V, Sechser T, Peter-kova M, Smid M, Biopharm. Drug Dispos. 1989, 10, 581-589.
13 Smith DA, Drug Metab. Rev. 1991, 23, 355-373.
14 Gombar CT, Harrington GW, Pylypiw HM, Anderson LM, Palmer AE, Rice JM, Magee PN, Burak ES, Cancer Res. 1990,
50, 4366-4370.
15 Chou WL, Robbie G, Chung SM,
Wu T-C, Ma C, Pharm. Res. 1998, 15, 1474-1479.
16 Ings RMJ, Xenobiotica 1990, 20, 1201-1231.
17 Campbell DB, Ings RMJ, Hum. Toxicol. 1988, 7, 469-479.
18 Lave T, Coassolo P, Reigner B, Clin. Pharmacokinet. 1999, 36, 211-231.
19 Lave T, Dupin S, Schmitt C, Chou RC, Jaeck D, Coassolo P, J. Pharm. Sci.
1997, 86, 584-590.
20 Smith DA, Jones BC, Walker DK,
Med. Res. Rev. 1996, 16, 243-266.
21 Lave T, Coassolo P, Ubeaud G,
Bradndt R, Schmitt C, Dupin S,
Jaeck D, Chou RC, Pharm. Res. 1996, 13, 97-101.
22 Gardner IB, Walker DK, Lennard MS, Smith DA, Tucker GT, Xenobiotica
1995, 25, 185-197.
23 Dack KN, Dickinson RP, Long CJ, Steele J, Bioorg. Med. Chem. Lett. 1998, 8, 2061-2066.
24 Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Knott S, Ruane RJ, Xenobiotica 1991, 21, 1243-1256.
25 Illing HPA, Fromson JM, Drug Metab. Dispos. 1978, 6, 510-517.
26 Lave T, Portmann R, Schenker G, Gianni A, Guenzi A, Girometta M-A, Schmitt M, J. Pharm. Pharmacol. 1999,
51, 85-91.
27 Mahmood I, J. Pharm. Pharmacol 1998, 50, 493-499.
Pharmacokinetics and Metabolism in Drug Design 133 Edited by D. A. Smith, H. van de Waterbeemd, D. K. Walker, R. Mannhold, H. Kubinyi, H. Timmerman I
Copyright © 2001 Wiley-VCH Verlag GmbH ISBNs: 3-527-30197-6 (Hardcover); 3-527-60021-3 (Electronic)
High(er) Throughput ADME Studies
ADME Absorption, distribution, metabolism, excretion
CYP3A4 Cytochrome P450 3A4
DMPK Drug metabolism and pharmacokinetics
HTS High throughput screening
MTS Medium throughput screening
P-gp P-glycoprotein
PK Pharmacokinetics
UHTS Ultra-high throughput screening
The HTS Trend
New approaches to medicinal chemistry such as parallel synthesis and combinatorial chemistry strategies [1] and refinement of high throughput screening in biology place Drug Discovery at a crossroads. Will traditional rationale medicinal chemistry continue as the cornerstone of how we discover drugs or will shear numbers of compounds be the winning formula. High compound numbers are essential whatever the eventual scenario to ensure that early lead matter is available. The size of compound files of the future, millions of compounds, means informatics and automation are key ingredients for a successful drug discovery organization [2]. How much drug metabolism needs to adapt is part of the question. Clearly many of the in vitro approaches can be automated and thus increase efficiencies. These systems are equally adaptable to screening a file or providing fast turnaround on newly synthesized products of a rationale discovery programme. Both approaches are being pursued. This chapter discusses the place of ADME screens and describes some of the recent developments which give insight into how medicinal chemistry, in a not too far future, may benefit.
134 | 10 High(er) Throughput ADME Studies
Drug Metabolism and Discovery Screening Sequences
The development of higher throughput approaches in ADME studies is driven by the advances in high-speed chemistry and pharmacological screening [3], a view of the future where many more compounds would need to be screened, and the availability of the technology. Departments of Drug Metabolism and Pharmacokinetics in the pharmaceutical industry are organizing themselves for the rapid evaluation of large numbers of compounds [4-8]. Higher throughput can move a screening approach up the traditional sequence, provide more comprehensive data on a single compound, or just screen more compounds or even files. The pre-ADME days of Discovery had screening sequences based on an in vitro functional response often followed by an oral rodent pharnmacodynamic model. The advent of ADME, cloned receptors etc., has led to the hierarchical sequence shown in Figure 10.1. Higher throughput could allow a parallel process, which collects large amounts of in vitro pharmacology and ADME data as the primary stage.
Previous << 1 .. 46 47 48 49 50 51 < 52 > 53 54 55 .. 56 >> Next